Clinical Trials Logo

Type 2 Diabetes clinical trials

View clinical trials related to Type 2 Diabetes.

Filter by:

NCT ID: NCT05333835 Active, not recruiting - Type 2 Diabetes Clinical Trials

A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes

Start date: July 8, 2022
Phase: Phase 2
Study type: Interventional

The aim of this trial is to compare the efficacy and safety of HR17031 versus INS068 and SHR20004 in subjects with type 2 diabetes.

NCT ID: NCT05261841 Active, not recruiting - Type 2 Diabetes Clinical Trials

Predictive Model on the Effect of Lifestyles in the Management of T2D

GK_T2D
Start date: June 26, 2021
Phase:
Study type: Observational

This study aims to produce new evidence on the positive effects of physical activity and certain individual lifestyles in the control of type 2 diabetic disease. The goal is to build and evaluate the effectiveness of a new parsimonious risk prediction model based on the use of classical variables (blood exams), already used in other models for predicting the risk related to the disease, together with measures obtained from the use of wearable devices (steps count, sleep hours, heart rate).

NCT ID: NCT05229718 Active, not recruiting - Type 2 Diabetes Clinical Trials

Understanding and Optimizing Care for Young Adults With Type 1 and Type 2 Diabetes Mellitus Transitioning to Adult Care

Start date: October 1, 2021
Phase: N/A
Study type: Interventional

In this study, we will determine the feasibility of an innovative care model for young adults with diabetes and compare the primary and secondary outcomes in the innovative model to those in the usual care model for adult diabetes management at Massachusetts General Hospital (MGH) Diabetes Center.

NCT ID: NCT05226897 Active, not recruiting - Type 2 Diabetes Clinical Trials

Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients

Start date: July 12, 2021
Phase: Phase 3
Study type: Interventional

Phase 3 study to assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients

NCT ID: NCT05214573 Active, not recruiting - Type 2 Diabetes Clinical Trials

Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk

Start date: December 1, 2021
Phase:
Study type: Observational

We will use the target trial framework for causal inference to conduct this observational retrospective cohort study that uses claims data of adults with type 2 diabetes (T2D) included in the de-identified datasets of OptumLabs Data Warehouse (OLDW) and Medicare fee-for-service. In Aim 1, we will emulate a target trial comparing the effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RA), sodium-glucose cotransporter 2 inhibitors (SGLT2i), dipeptidyl peptidase-4 inhibitors (DPP-4i), and sulfonylureas (SU) in adults with T2D at moderate risk of cardiovascular disease (CVD) with regard to major adverse cardiovascular events (MACE), expanded MACE, microvascular complications, severe hypoglycemia, and other adverse events. In Aim 2, we will compare these four drug classes in the same population of adults with T2D included in OLDW and Medicare fee-for-service data with respect to a set of composite outcomes identified by a group of patients with T2D as being most important to them. Specifically, in Aim 2A, we will prospectively elicit patient preferences toward various treatment outcomes (e.g., hospitalization, kidney disease) using a participatory ranking exercise, then use these rankings to generate individually weighted composite outcomes. Then, in Aim 2B, we will estimate patient-centered treatment effects of four different second-line T2D medications that reflect the patient's value for each outcome. In Aim 3, we will compare different medications within each of the four therapeutic classes with respect to MACE.

NCT ID: NCT05181449 Active, not recruiting - Type 2 Diabetes Clinical Trials

Randomized Controlled Trial of Digital Twin Precision Treatment: A Novel Whole Body Digital Twin Enabled Precision Treatment for Type 2 Diabetes

TPT
Start date: February 1, 2022
Phase: N/A
Study type: Interventional

This is a randomized study comparing outcomes of patients diagnosed with Type 2 Diabetes (T2D) who are enrolled into the Twin Health Precision Treatment (TPT) system versus usual care. The study will last for a year with a 1 year optional extension for the TPT arm patients to continue for another year, and for the usual care (UC) patients to cross over to the TPT treatment for a year. 150 patients will be enrolled with 100 being randomized to the TPT arm and 50 being enrolled to the UC arm

NCT ID: NCT05174078 Active, not recruiting - Obesity Clinical Trials

Food as Medicine: A Quasi-Randomized Control Trial of Healthy Foods for Chronic Disease Management

Start date: February 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the effect of providing healthy foods and nutrition education on participants' body weight, blood pressure, and average blood sugar level. The healthy food offerings tested in this study will help determine which option is best to improve health outcomes among Cleveland Clinic Akron General patients with chronic conditions. Findings from this study could guide doctors in deciding on appropriate nutrition and dietitian services for Cleveland Clinic patients.

NCT ID: NCT05170867 Active, not recruiting - Obesity Clinical Trials

The Impact of Hafnia Alvei on Weight Loss and Glycaemic Control After Bariatric Surgery

Start date: January 14, 2022
Phase: N/A
Study type: Interventional

This study aims to investigate the effects of Hafnia alvei HA4597 TM supplementation on weight loss and glycemic control after bariatric surgery. Patients undergoing Roux-en-Y gastric bypass will receive probiotics or placebo, twice a day, for 90 days, one month after surgery. Outcomes will be measured at baseline, and 3, 6, 9 and 12 months after the surgery.

NCT ID: NCT05166382 Active, not recruiting - Clinical trials for Cardiovascular Diseases

Impact of SomaSignal Tests on the Choice of Glucose-lowering Medications

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to learn more about using a proteomic test called the SomaSignal Cardiovascular (CV) Risk Test in Type 2 Diabetes (CVD-T2D) to improve medical care for patients.

NCT ID: NCT05066542 Active, not recruiting - Type 2 Diabetes Clinical Trials

Recreational Basketball to Increase Participation in Diabetes Prevention

DPPHoops
Start date: June 11, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the efficacy of adapting the National Diabetes Prevention Program (NDPP) to include recreational sports in effort to increase physical activity (PA) and promote lifestyle changes that can help reduce the risk of developing Type 2 Diabetes Mellitus. The hypothesis is that both the traditional NDPP and the NDPP+ Basketball will be considered feasible. The primary outcome is to assess whether the intervention (NDPP+BB) compared to the standard of care (NDPP only) will result in greater weight loss, lower A1c, and increased engagement in physical activity.